🎉 M&A multiples are live!
Check it out!

ARS Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for ARS Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

ARS Pharmaceuticals Overview

About ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.


Founded

2016

HQ

United States of America
Employees

160

Website

ars-pharma.com

Financials

LTM Revenue $87.4M

LTM EBITDA -$44.5M

EV

$1.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ARS Pharmaceuticals Financials

ARS Pharmaceuticals has a last 12-month revenue of $87.4M and a last 12-month EBITDA of -$44.5M.

In the most recent fiscal year, ARS Pharmaceuticals achieved revenue of $89.1M and an EBITDA of -$3.1M.

ARS Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ARS Pharmaceuticals valuation multiples based on analyst estimates

ARS Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $30K $89.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$67.5M -$3.1M XXX XXX XXX
EBITDA Margin -225067% -3% XXX XXX XXX
Net Profit -$34.7M -$54.4M XXX XXX XXX
Net Margin -115607% -61% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ARS Pharmaceuticals Stock Performance

As of April 15, 2025, ARS Pharmaceuticals's stock price is $14.

ARS Pharmaceuticals has current market cap of $1.4B, and EV of $1.1B.

See ARS Pharmaceuticals trading valuation data

ARS Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.1B $1.4B XXX XXX XXX XXX $-0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ARS Pharmaceuticals Valuation Multiples

As of April 15, 2025, ARS Pharmaceuticals has market cap of $1.4B and EV of $1.1B.

ARS Pharmaceuticals's trades at 12.7x LTM EV/Revenue multiple, and -24.8x LTM EBITDA.

Analysts estimate ARS Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ARS Pharmaceuticals and 10K+ public comps

ARS Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.1B XXX XXX XXX
EV/Revenue 12.4x XXX XXX XXX
EV/EBITDA -358.7x XXX XXX XXX
P/E 177.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 85.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ARS Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ARS Pharmaceuticals Valuation Multiples

ARS Pharmaceuticals's NTM/LTM revenue growth is 38%

ARS Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, ARS Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ARS Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ARS Pharmaceuticals and other 10K+ public comps

ARS Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 297063% XXX XXX XXX XXX
EBITDA Margin -3% XXX XXX XXX XXX
EBITDA Growth -95% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 35% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 22% XXX XXX XXX XXX
Opex to Revenue 102% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ARS Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ARS Pharmaceuticals M&A and Investment Activity

ARS Pharmaceuticals acquired  XXX companies to date.

Last acquisition by ARS Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . ARS Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ARS Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ARS Pharmaceuticals

When was ARS Pharmaceuticals founded? ARS Pharmaceuticals was founded in 2016.
Where is ARS Pharmaceuticals headquartered? ARS Pharmaceuticals is headquartered in United States of America.
How many employees does ARS Pharmaceuticals have? As of today, ARS Pharmaceuticals has 160 employees.
Who is the CEO of ARS Pharmaceuticals? ARS Pharmaceuticals's CEO is Mr. Richard E. Lowenthal, M.B.A.,M.S..
Is ARS Pharmaceuticals publicy listed? Yes, ARS Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of ARS Pharmaceuticals? ARS Pharmaceuticals trades under SPRY ticker.
When did ARS Pharmaceuticals go public? ARS Pharmaceuticals went public in 2022.
Who are competitors of ARS Pharmaceuticals? Similar companies to ARS Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ARS Pharmaceuticals? ARS Pharmaceuticals's current market cap is $1.4B
What is the current revenue of ARS Pharmaceuticals? ARS Pharmaceuticals's last 12-month revenue is $87.4M.
What is the current EBITDA of ARS Pharmaceuticals? ARS Pharmaceuticals's last 12-month EBITDA is -$44.5M.
What is the current EV/Revenue multiple of ARS Pharmaceuticals? Current revenue multiple of ARS Pharmaceuticals is 12.7x.
What is the current EV/EBITDA multiple of ARS Pharmaceuticals? Current EBITDA multiple of ARS Pharmaceuticals is -24.8x.
What is the current revenue growth of ARS Pharmaceuticals? ARS Pharmaceuticals revenue growth between 2023 and 2024 was 297063%.
Is ARS Pharmaceuticals profitable? Yes, ARS Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.